E2 Secures Dual FDA Clearances for the Hēlo® Platform, Introducing a PE Thrombectomy System with Integrated Blood Return
Combination of Hēlo Thrombectomy System and Hēlo Return establish the first 510(k)-cleared platform compatible with continuous vacuum aspiration MENLO PARK, Calif., Oct. 12, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on...
Covered in this story
Call it yourself
No calls on $PARK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Park Dental Partners →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.